Big pharma dominates ranking of stocks with best five-year returns
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Baird Cuts Price Target on Regeneron (REGN) to $505; Reiterates Outperform
May 5, 2016 3:25 PM EDTBaird maintained an Outperform rating on Regeneron Pharma (NASDAQ: REGN), and cut the price target to $505.00 (from $526.00), following the company's 1Q earnings report. EPS of $2.57 was reported in-line with expectations. Baird continues to believe that the copmant can deliver growth over the next few... More
Oppenheimer Cuts Price Target as Gilead Sciences (GILD) Reports 1Q Miss
May 4, 2016 8:43 AM EDTOppenheimer maintained an Outperform rating on Gilead Sciences (NASDAQ: GILD), and cut the price target to $116.00 (from $120.00), following the company's 1Q earnings report. Gilead reported 1Q16 revenues of $7.79B, below consensus estimates of $8.06B. The top line miss was due to soft sales from... More
Leerink Modestly Positive on Biogen's (BIIB) Hemophilia Spin; Remains Cautious on Rest of Company
May 3, 2016 2:52 PM EDTLeerink affirms Biogen (Nasdaq: BIIB) with a Market Perform rating and $319 price target following news that the company is going to spin-off its hemophilia unit.
Analyst Geoffrey Porges commented: In a somewhat surprising move, Biogen announced today that it will spin off its hemophilia business into an... More
